Logo

Lupin's Solosec (secnidazole) Receives the US FDA's Approval for the Treatment of Trichomoniasis

Share this

Lupin's Solosec (secnidazole) Receives the US FDA's Approval for the Treatment of Trichomoniasis

Shots:

  • The approval is based on a P-III clinical trial that involves assessing Solosec (2g- PO- granules) vs PBO in 64 patients with trichomoniasis
  • The P-III trial demonstrated 92.2% cure rate in the modified ITT population and 94.9% in the per-protocol population- therapy was well-tolerated with no serious AEs were identified in the trial
  • Additionally- the study demonstrated that ~70% of women with trichomoniasis are PCR positive for BV. Solosec (secnidazole) is the first single-dose oral prescription approved to treat both trichomoniasis & BV in the US

  | Ref: Lupin | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions